Bio-Rad Laboratories, Inc.

Good afternoon, ladies and gentlemen, and welcome to the Q2 2021 BioRad Laboratories, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press star zero on your touchtone telephone. I would now like to turn the conference over to your host, Mr. Edward Chung, Head of Investor Relations. Sir, please go ahead.

Thank you, Joanna. Good afternoon. Thank you all for joining us. Today, we will review the second quarter 2021 financial results and provide an update on key business trends for Bio-Rad. With me on the phone today are Norman Schwartz, our Chief Executive Officer, Ilan Daskal, Executive Vice President and Chief Financial Officer, and the last, Executive Vice President and Chief Operating Officer, Annette Tumulon, President of the Live Science Group, Andara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans, expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on BI-RAD's results, operations, and steps BI-RAD is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. With that, I will now turn the call over to Ilan Dasko, our Executive Vice President and Chief Financial Officer.

Thank you, Ed. Good afternoon. Thank you all for joining us, and we hope that you and your families are well and staying healthy during these challenging times. And also, we want to officially welcome Edward Chang as our Head of Investor Relations. Before I begin the detailed second quarter discussion, I would like to ask Andy Lust, our Chief Operating Officer, to provide an update on bioret operations in light of the current pandemic-related environment that we are experiencing globally. Andy?